måndag 2 november 2026

SAAR dieetin mahdollsesta merkityksestä, Seriinin de novo synteesi tehostuu.

 https://www.sciencedirect.com/science/article/pii/S2212877826000098

HIGHLIGHTS

  • •
    Dietary SAAR increases glucose partitioning to liver de novo serine synthesis.
  • •
    Deletion of liver PSAT1 abrogates improvements in glucose tolerance by SAAR.
  • •
    SAAR lowers lysine lactoylation, a SAA-supported post-translational modification known to inhibit serine synthesis enzymes.
  • •
    Hepatic PSAT1 is not necessary for SAAR to lower adiposity and liver triglycerides.

Abstract

Dietary sulfur amino acid restriction (SAAR) improves whole-body glucose homeostasis, elevates liver insulin action, and lowers liver triglycerides. These adaptations are associated with an increased expression of hepatic de novo serine synthesis enzymes, phosphoglycerate dehydrogenase (PHGDH) and phosphoserine aminotransferase 1 (PSAT1). This study tested the hypothesis that enhanced hepatic serine synthesis is necessary for glucose and lipid adaptations to SAAR. Hepatocyte-specific PSAT1 knockout (KO) mice and wild type (WT) littermates were fed a high-fat control or SAAR diet. In WT mice, SAAR increased liver PSAT1 protein (∼70-fold), serine concentration (∼2-fold), and 13C-serine (∼20-fold) following an intravenous infusion of [U–13C]glucose. The elevated liver serine and partitioning of circulating glucose to liver serine by SAAR were attenuated in KO mice. This was accompanied by a blunted improvement in glucose tolerance in KO mice fed a SAAR diet. Interestingly, SAAR decreased liver lysine lactoylation, a SAA-supported post-translational modification known to inhibit PHGDH enzymatic activity. This suggests dietary SAAR may increase serine synthesis, in part, by lowering lysine lactoylation. Beyond glucose metabolism, dietary SAAR reduced body weight, adiposity, and liver triglycerides similarly in WT and KO mice. Collectively, these results demonstrate that hepatic PSAT1 is necessary for glucose, but not lipid, adaptations to SAAR.
...
Elevated expression of liver de novo serine synthesis pathway enzymes, phosphoglycerate dehydrogenase (PHGDH) and phosphoserine aminotransferase 1 (PSAT1), is among the most reproducible responses to dietary SAAR, making their increase a marker of a successful dietary intervention [2,9,10]; [[15], [16], [17], [18], [19], [20], [21], [22], [23]]. De novo serine synthesis is sourced from 3-phosphoglycerate, an intermediate of both glycolysis and gluconeogenesis [24]. Thus, a SAAR-mediated increase in hepatic serine synthesis could promote greater glucose disposal and/or divert gluconeogenic flux away from glucose production. 

SULFUROMI tiedettä , SAAR- dieetti näkee S-molekyylin osuuden metaboliassa. Se taitaa olla vahvempi tasapainottaja S:N suhteessa ja korjaa itsensä perusteella.

 https://pubmed.ncbi.nlm.nih.gov/38776754/

Ravinto-opin kirjan  mielenkiintoinen lakonisesti  kerrottu molekyyli S. 

Ihmisen kudoksissa S: N suhde on vakio:  rakenteellisessa kudoksessa., 

Aiemmin tietona oli 1:6 jostain  ehkä rakentnetasosta. AI sanoo nyt  1:14,5 ehkä toiminnallisesta tasosta ja vegandieetillä 1:20.

Abstract

Background: In animals, dietary sulfur amino acid restriction (SAAR) improves metabolic health, possibly mediated by altering sulfur amino acid metabolism and enhanced anti-obesogenic processes in adipose tissue.

Aim: To assess the effects of SAAR over time on the plasma and urine SAA-related metabolites (sulfurome) in humans with overweight and obesity, and explore whether such changes were associated with body weight, body fat and adipose tissue gene expression.

Methods: Fifty-nine subjects were randomly allocated to SAAR (∼2 g SAA, n = 31) or a control diet (∼5.6 g SAA, n = 28) consisting of plant-based whole-foods and supplemented with capsules to titrate contents of SAA. Sulfurome metabolites in plasma and urine at baseline, 4 and 8 weeks were measured using HPLC and LC-MS/MS. mRNA-sequencing of subcutaneous white adipose tissue (scWAT) was performed to assess changes in gene expression. Data were analyzed with mixed model regression. Principal component analyses (PCA) were performed on the sulfurome data to identify potential signatures characterizing the response to SAAR.

Results: SAAR led to marked decrease of the main urinary excretion product sulfate (p < 0.001) and plasma and/or 24-h urine concentrations of cystathionine, sulfite, thiosulfate, H2S, hypotaurine and taurine. PCA revealed a distinct metabolic signature related to decreased transsulfuration and H2S catabolism that predicted greater weight loss and android fat mass loss in SAAR vs. controls (all pinteraction < 0.05). This signature correlated positively with scWAT expression of genes in the tricarboxylic acid cycle, electron transport and β-oxidation (FDR = 0.02).

Conclusion: SAAR leads to distinct alterations of the plasma and urine sulfurome in humans, and predicted increased loss of weight and android fat mass, and adipose tissue lipolytic gene expression in scWAT. Our data suggest that SAA are linked to obesogenic processes and that SAAR may be useful for obesity and related disorders. TRIAL IDENTIFIER: https://clinicaltrials.gov/study/NCT04701346.

Keywords: Adipose tissue; Cysteine; Gene expression; Hydrogen sulfide; Methionine; Randomized controlled trial; Sulfur amino acid restriction; Transsulfuration.